Skip to content

Clinical evaluation and application of test reference interval in old adults

Clinical evaluation and application of test reference interval in old adults

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070831
Enrollment
Unknown
Registered
2023-04-24
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, subclinical hypothyroidism, primary osteoporosis, heart failure, lung cancer

Interventions

Primary osteoporosis group:none
Subclinical hypothyroidism group:none

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 89 Years

Inclusion criteria

Inclusion criteria: 1.Outpatients and inpatients aged 60-89. 2.voluntarily participate, sign the informed consent form, and cooperate to complete all the inspection contents in the project. 3.take care of themselves, without major diseases such as dementia, disability, severe liver and kidney insufficiency, and so on.

Exclusion criteria

Exclusion criteria: 1.refuse to visit midway for various reasons. 2.can does not cooperate with the project team to complete all the inspection contents and other limiting factors. 3.There were non-research factors affecting the related test items (glycosylated hemoglobin, glycosylated albumin, thyrotropin, ß-glue degradation products, N-terminal Pro peptide of type I procollagen, osteocalcin, bone alkaline phosphatase, BNP, NT-proBNP, carcinoembryonic antigen, neuron-specific enolase, cytokeratin 19 fragment antigen, gastrin-releasing peptide precursor, squamous cell carcinoma antigen).

Design outcomes

Primary

MeasureTime frame
Glycosylated hemoglobin;glycosylated albumin;Thyroid stimulating hormone;ß-glued degradation products;N-terminal propeptide of type I procollagen;osteocalcin;bone alkaline phosphatase;BNP(Brain natriuretic peptide);NT-proBNP(N-terminal pro-brain natriuretic peptide);carcinoembryonic antigen;neuron specific enolase;cytokeratin 19 fragment antigen;gastrin releasing peptide precursor;squamous cell carcinoma antigen;

Secondary

MeasureTime frame
QALYs(Quality-adjusted life years);Health utility value;

Countries

China

Contacts

Public ContactJun Li

West China Hospital, Sichuan University

jundream2013@163.com+86 18980602112

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 3, 2026